Evidence-Based Complementary and Alternative Medicine

Evidence-Based Complementary and Alternative Medicine / 2018 / Article

Research Article | Open Access

Volume 2018 |Article ID 8041820 | 10 pages | https://doi.org/10.1155/2018/8041820

Electroacupuncture at Hua Tuo Jia Ji Acupoints Reduced Neuropathic Pain and Increased GABAA Receptors in Rat Spinal Cord

Academic Editor: Alfredo Vannacci
Received09 Nov 2017
Accepted06 Jun 2018
Published04 Jul 2018


Chronic constriction injury- (CCI-) induced neuropathic pain is the most similar model to hyperalgesia in clinical observation. Neuropathic pain is a neuronal dysfunction in the somatosensory system that may lead to spontaneous pain. In this study, electroacupuncture (EA) was applied at bilateral L4 and L6 of Hua Tuo Jia Ji points (EX-B2) for relieving neuropathic pain in rats. Eighteen Sprague-Dawley rats were randomly assigned to three groups: sham, 2-Hz EA, and 15-Hz EA groups. Following von Frey and cold plate tests, both the 2- and the 15-Hz EA groups had significantly lower mechanical and thermal hyperalgesia than the sham group. Western blot analysis results showed that γ-aminobutyric acid A (GABAA), adenosine A1 receptor (A1R), transient receptor potential cation channel subfamily V member 1 (TRPV1), TRPV4, and metabotropic glutamate receptor 3 (mGluR3) were similar in the dorsal root ganglion of all three groups. Furthermore, levels of GABAA receptors were higher in the spinal cord of rats in the 2- and 15-Hz EA groups compared with the sham control group. This was not observed for A1R, TRPV1, TRPV4, or mGluR3 receptors. In addition, all the aforementioned receptors were unchanged in the somatosensory cortex of the study rats, suggesting a central spinal effect. The study results provide evidence to support the clinical use of EA for specifically alleviating neuropathic pain.

1. Introduction

According to the International Association for the Study of Pain, neuropathic pain is defined as pain caused by a lesion or disease of the somatosensory system [1]. Pain resulting from neuropathic pain is always accompanied by depression, anxiety, and sleep disturbance [2, 3]. Neuropathic pain can be further subdivided into peripheral and central neuropathy. Peripheral neuropathy includes painful diabetic neuropathy, human immunodeficiency virus-associated neuropathy, hemotherapy-induced peripheral neuropathy, and postherpetic neuralgia. By contrast, central neuropathy includes spinal injury, central poststroke pain, and compressive myelopathy among other conditions. Unbalanced neurotransmitters or neuromodulators always mismatch painful sensory inputs, which results in the generation of spontaneous painful sensations. In neuropathic pain, spontaneous mechanical or thermal hyperalgesia is often observed, and several central sensitizations are induced in the dorsal horn of the spinal cord (SC), such as sodium channels, N-methyl-d-aspartate (NMDA), γ-aminobutyric acid (GABA), and opioid receptors [4]. Medicines such as aspirin, acetaminophen, nonsteroidal anti-inflammation drugs, antidepressants, and opiates are currently used to treat neuropathic pain with limited success and side effects [5].

Adenosine is released from presynaptic terminals to bind postsynaptic A1, A2A, A2B, and A3 receptors for cardiovascular, immune, and nerve functions [6, 7]. Adenosine A1 receptor (A1R) is located mainly in peripheral sensory terminal [8], SC [9], and glial cells [10, 11]. Activation of A1R produced an analgesic effect in inflammatory and neuropathic pain models [12, 13]. A1R is reported to activate Gi protein and inhibit the cyclic adenosine monophosphate-protein kinase A pathway [14]. Injection of adenosine can reliably attenuate allodynia and hyperalgesia in many pain symptoms [7, 15]. However, several side effects result from activation of adenosine A2 receptor (A2R). It may induce vasodilation, a reduced heart rate, and severe cardiovascular obstacles.

GABA receptors are the main inhibitory neurotransmitters in the mammalian central nervous system. GABA receptors can be further subdivided into GABAA, GABAB, and GABAC. GABAA is an ion channel that mediates fast inhibitory synaptic transmission and induces an influx of chloride, leading to stability of the neuronal membrane. Several factors can activate GABAA for reducing neuronal excitability, and these are often used for anesthesia and pain management. Injection of GABA agonists is considered to be the most effective method of reducing pain signaling [16, 17]. In neuropathic pain, GABAergic interneurons initiate apoptosis via the caspase-3 pathway [18]. In addition, after nerve injury, GABA and glutamate decarboxylase 65 have been reported to be lower [19, 20].

The transient receptor potential (TRP) is a nonselective ion channel that can be activated following a tissue injury [21]. Transient receptor potential cation channel subfamily V member 1 (TRPV1) exists in nociceptors and the SC dorsal horn for pain signaling [22, 23]. TRPV1 can be activated by capsaicin, noxious heat (more than 43°C), and mechanical sensation [2426]. TRPV1 is highly expressed in small C-fiber dorsal root ganglion (DRG) neurons and trigeminal and nodose ganglia [27]. Activation of TRPV1 induces sodium and calcium influx for neuronal depolarization [28, 29]. Depletion of TRPV1 gene results in insensitivity to noxious heat, radial heat, and hot-plate tests [30]. Inflammatory-material-induced thermal hyperalgesia was attenuated in TRPV1 knockout mice, suggesting the crucial role of TRPV1 in thermal pain sensation [31].

TRPV4 is a polymodal receptor that acts as an osmotic, mechanical, and thermal receptor [32]. Activation of TRPV4 releases calcitonin gene-related peptide and substance P into the SC dorsal horn [33]. TRPV4 is widely expressed in hair cells, kidney, lung, and peripheral sensory ganglia [34]. TRPV4 expressed in heterologous systems is usually activated by osmotic stimuli, resulting in cell swelling [35]. TRPV4 may also participate in the reduction of visceral pain [32]. Coexpression of TRPV1 and TRPV4 may synergistically play a role in nociception [36].

Neuropathic pain from surgery may damage c- and Aδ fibers to increase the release of glutamate. Glutamate is a major excitatory neurotransmitter in the mammalian central nervous system that is released from presynaptic terminals for binding on four receptor subtypes: α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid, NMDA, KA, and metabotropic glutamate receptor (mGluR) [37]. mGluR was indicated to be involved in neuropathic pain [38].

Acupuncture has been used for treating diseases for thousands of years. Increasing evidence suggests that electroacupuncture (EA) can be used to treat learning and memory impairment in ischemia rats [39], epilepsy [40], body weight control [41], and pain [42, 43]. Accordingly, the aim of the present study was to identify whether EA applied at Hua Tuo Jia Ji acupoints could reduce chronic constriction injury- (CCI-) induced neuropathic pain in rat models. We further investigated whether A1R, GABAA, TRPV1, TRPV4, and mGluR3 participate in the EA analgesic effect by evaluating DRG, SC, and somatosensory cortex (SSC) levels.

2. Materials and Methods

2.1. Animals

Eighteen male Sprague-Dawley rats weighing 201–250 g were purchased from BioLASCO (BioLASCO Taiwan Co., Ltd) and housed in the animal center of China Medical University (CMU). A 12-12-h light-dark cycle was maintained, and the room temperature was controlled at 25°C. Adequate food and water were provided. The Animal Care and Use Committee of CMU approved the use of these animals. In addition, all procedures were performed according to the Guide for the Use of Laboratory Animals (National Academy Press). The CCI model is often used to mimic clinical neuropathic pain by “tying 4-0 chromic gut sutures” in the sciatic nerve with the phenotype of hyperalgesia and allodynia. CCI was induced on the right sciatic nerve of rats, and their pain behavior was tested on day 5 to ensure the establishment of neuropathic pain. The sample size required an effect size of 0.6 in withdrawal threshold and an alpha of 0.05, and a power of 80%  was estimated to be 6 animals per group. Rats were randomly subdivided into three groups (n = 6/group): (1) sham, (2) 2-Hz EA, and (3) 15-Hz EA groups. Rats were anesthetized with 3%  isoflurane, and their right sciatic nerve was exposed. Furthermore, the nerve proximal to the trifurcation was ligated using four 4-0 chromic gut sutures. The surgical site was closed immediately using silk line before the rats were placed back in their cage.

2.2. EA Treatment

EA was applied at days 7, 8, and 9 using stainless steel needles (0.5′′, 32 G, Yu-Kuang, Taiwan) inserted into Hua Tuo Jia Ji acupoints at a depth of 2-3 mm, 5 mm from the spine at L4 and L6. EA was administered for 20 min immediately after the neuropathic injection. A stimulator (Trio 300, Ito, Japan) delivered 100-μs square pulses of 2 mA for 15 min at 2 or 15 Hz. For the sham control group, we only inserted the needle and connected the animals to the stimulator without current input.

2.3. Animal Behavior

The von Frey test was adopted to examine mechanical hyperalgesia (IITC; Life Science Inc., USA). Rats were placed on a metal mesh and stimulated by applying a thin filament at the hind paw. The forces were recorded automatically when the rats withdrew their right hind paw. The cold plate test was used to assess thermal hyperalgesia during which the rats were placed on a cold plate apparatus (Panlab, Spain), with the temperature at 4°C. The total number of foot lifts was counted (right hind paw) for 5 min. The laboratory workers kept blind to treatment allocation during the experiments and analysis.

2.4. Western Blot Analysis

Rat DRG, SC, and SSC were immediately excised at day 9 after behavior test for protein extraction. We followed the methods of Liao et al. 2016 [40]. Total protein was prepared by homogenizing the hippocampi for 1 h at 4°C in a lysis buffer containing 20 mmol/L imidazole-HCl (pH 6.8), 100 mmol/L KCl, 2 mmol/L MgCl2, 20 mmol/L ethylene glycol tetraacetic acid (pH 7.0), 300 mmol/L sucrose, 1 mmol/L NaF, 1 mmol/L sodium vanadate, 1 mmol/L sodium molybdate, 0.2%  Triton X-100, and a proteinase inhibitor cocktail. From each sample, 30 μg of protein was extracted and analyzed through a bicinchoninic acid protein assay. The extracted protein was subjected to 10%–15%  sodium dodecyl sulfate-Tris-glycine gel electrophoresis and transferred onto a nitrocellulose membrane. The membrane was blocked with 5%  nonfat milk in a TBST buffer (10 mmol/L Tris-buffered saline, pH 7.5; 100 mmol/L NaCl; and 0.1%  Tween 20) and incubated overnight at 4°C with the anti-GABAA antibody (1:1000, Alomone, Israel), anti-A1R antibody (1:1000, Alomone), anti-TRPV1 (1:1000, Alomone), anti-TRPV4 antibody (1:1000, Alomone), and anti-GluR3 antibody (1:1000, Alomone) in TBST containing bovine serum albumin. Peroxidase-conjugated antibody (1:500) was used as the secondary antibody. The membrane was assessed using the ECL-Plus protein detection kit.

2.5. Statistical Analysis

All data are presented as mean ± standard error. Statistically significant differences among the sham, 2-Hz EA, and 15-Hz EA groups were analyzed through one-way analysis of variance, followed by Tukey’s post hoc test. A p value less than 0.05 was considered statistically significant.

3. Results

We first used the von Frey test to ensure the induction of CCI-induced mechanical hyperalgesia. Our data showed that the CCI had initiated mechanical hyperalgesia from day 7 to day 9 after induction in the sham group (Figure 1(a); 11.77 ± 1.16 g, 15.76 ± 1.15 g, 14.4 ± 1.92 g, respectively). We next discovered that the 2-Hz EA group had significantly lower mechanical hyperalgesia than the sham group (Figure 1(a); 17.53 ± 0.79 g, 19.21 ± 1.69 g, 21.98 ± 1.47 g, respectively). Similar results were also observed in the 15-Hz EA group (Figure 1(a); 15.39 ± 2.04 g, 21.63 ± 3.86 g, 21.84 ± 2.89 g, respectively). Next, we performed the cold plate test to determine whether thermal hyperalgesia was involved in the CCI-initiated neuropathic pain. Our results indicated that CCI reliably induced thermal hyperalgesia from day 7 to day 9 in the sham group (Figure 1(b); number of hind paw lifts: 15.83 ± 1.05, 15.33 ± 2.01, 15.83 ± 3.44, respectively). In both the 2-Hz group (Figure 1(b); 10.4 ± 1.9, 10.8 ± 2.28, 6.8 ± 2.13) and 15-Hz group (Figure 1(b); 7.8 ± 1.85, 10.6 ± 2.18, 7.8 ± 2.48), EA successfully attenuated thermal hyperalgesia. Accordingly, we suggest that 2- and 15-Hz EA can reliably attenuate both mechanical and thermal hyperalgesia.

Western blot analysis was performed to clarify the involvement of receptors in the EA analgesia of CCI-induced neuropathic pain. Our results indicated that the protein levels of GABAA receptors in rat DRG were not changed in the sham, 2-Hz EA, and 15-Hz EA groups (Figure 2(a); 100.01%  ± 17.97%, 94.44%  ± 25.91%, and 90.17%  ± 14.62%, respectively; p > 0.05, n = 6). We next verified the effect of analgesic A1R on peripheral DRG neurons. We determined that there was no difference among the sham, 2-Hz EA, and 15-Hz EA groups (Figure 2(b); 100.01%  ± 7.6%, 86.01%  ± 16.43%, and 93.51%  ± 10.61%, respectively; p > 0.05, n = 6). The phenomenon was also observed for TRPV1 (Figure 2(c); 100.01%  ± 11.15%, 94.61%  ± 16.50%, and 96.81%  ± 11.53%; p > 0.05, n = 6), TRPV4 (Figure 2(d); 100.01%  ± 8.66%, 89.68%  ± 8.41%, and 99.81%  ± 10.95%; p > 0.05, n = 6), and mGluR3 (Figure 2(e); 100.04%  ± 28.14%, 101.16%  ± 19.23%, and 137.52%  ± 45.89%; p > 0.05, n = 6) expression in rat DRG.

We further analyzed the levels of the aforementioned receptors in the central SC. Our data demonstrated that both 2- and 15-Hz EA significantly increased the protein levels of GABAA receptors in rat SC (Figure 3(a); 124.79%  ± 9.86%  and 129.29%  ± 8.03%; p < 0.05, n = 6). We then evaluated whether analgesic A1R also participated in the EA process. Our results demonstrated that the potentiation was not observed in either the 2- or the 15-Hz EA group (Figure 3(b); 101.08%  ± 17.19% and 102.87%  ± 23.1%; p > 0.05, n = 6). This phenomenon was also not observed in TRPV1 (Figure 3(c); 100.09% ± 20.92%  and 107.64 ± 34.72; p > 0.05, n = 6), TRPV4 (Figure 3(d); 115.83% ± 20.39%  and 104.05%  ± 14.97%; p > 0.05, n = 6), or mGluR3 (Figure 3(e); 101.08%  ± 14.34%  and 102.87%  ± 22.65%; p > 0.05, n = 6) expression in SC.

Furthermore, we further tested whether these receptors were involved in EA analgesia in the rat SSC. Neither 2- nor 15-Hz EA altered the protein levels of GABAA receptors in rat SSC (Figure 4(a); 112.84%  ± 24.48%  and 99.81%  ± 26.06%; p > 0.05, n = 6). We next showed that A1R did not participate in EA analgesia because the protein level was not altered in either the 2- or the 15-Hz EA group (Figure 4(b); 109.28%  ± 22.05%  and 95.05%  ± 17.43%; p > 0.05, n = 6). Protein levels remained unchanged in TRPV1 (Figure 4(c); 109.84%  ± 4.55%  and 94.56%  ± 6.13%; p > 0.05, n = 6), TRPV4 (Figure 4(d); 99.5%  ± 2.23%  and 98.48%  ± 3.76%; p > 0.05, n = 6), and mGluR3 (Figure 4(e); 109.73% ± 14.87%  and 114.98% ± 13.38%; p > 0.05, n = 6) expressions in the rat cortex.

4. Discussion

EA has been widely used for pain relief. A recent study [44] indicated that high-frequency (100-Hz) EA obtained superior results to low-frequency (2-Hz) EA in the rat ankle sprain pain model. EA can relieve acute pain by releasing opiates to activate μ-, δ-, and κ-opioid receptors. By contrast, EA can regulate persistent pain by activating μ- and δ-opioid receptors [45]. Abuaisha et al. [46] suggested that acupuncture is a potential treatment for chronic painful peripheral diabetic neuropathy. Cruccu et al. [47] stated that pharmacological relief of neuropathic pain is always insufficient. Electrical neurostimulation is therapeutic in chronic neuropathic pains. One study suggested that EA is more favorable than high-frequency transcutaneous electrical nerve stimulation. Our previous study [48] demonstrated that EA at Zusanli and Shangjuxu acupoints significantly reduced both mechanical and thermal hyperalgesia by reducing cerebral TRPV4 expressions but not TRPV1 expression.

EA at 2 Hz can reduce pain depending on the noradrenergic descending pathway and spinal GABAergic modulation. By contrast, high-frequency EA at 100 Hz mainly acts on GABAB mechanisms [49]. EA at 2 Hz can reliably decrease pain signaling through GABAA in the dorsal anterior pretectal nucleus. Furthermore, 100-Hz EA can attenuate pain via μ-opioid and 5-hydroxytryptamine 1 (5-HT1) receptors in the ventral anterior pretectal nucleus [49]. Fusumada et al. [50] suggested that EA at the ST36 acupoint may regulate GABAergic transmission on descending pathways in periaqueductal areas. Injection of a GABA receptor agonist, gabazine or saclofen, attenuated the therapeutic effect of EA on cold allodynia in rats. These results indicate the crucial role of both GABAA and GABAB receptors in neuropathic rats at spinal levels [51]. Xing et al. [52] demonstrated that neuronal hyperactivity in spinal pain transmission was enhanced after nerve injury and further developed into neuropathic pain. EA at 2 Hz was curative in neuropathic pain with the expression of LTD in the C-fiber in SNL rats. The phenomenon could be blocked by NMDA and an opioid receptor antagonist. By contrast, 100-Hz EA induced LTP in SNL rats, which was mainly mediated by endogenous GABAergic and serotonergic inhibitory systems [52]. In this study, EA administered at Hua Tuo Jia Ji acupoints reduced neuropathic pain by increasing the protein level of GABAA receptor in the SC.

Goldman et al. [53] determined that adenosine was released during manual acupuncture to activate adenosine A1 but not A2 receptors. They also showed that direct injection of A1R agonist could mimic the analgesic effect of acupuncture. Inhibition of adenosine-degradation enzymes enhanced the concentration of adenosine that was positively related to pain relief [53]. Acupuncture and adenosine agonist injected into Zusanli acupoints significantly reduced electrical pain signals in the anterior cingulate cortex. The phenomenon was majorly mediated by the activation of A1R but not A2R. A recent study [54] also showed that interstitial adenosine concentration was increased through acupuncture at the ST36 acupoint for 30 minutes. The phenomenon was only observed at acupoints with rotation, but not when the needle was delivered without rotation or with rotation at a nonacupoint. Intrathecal injection of adenosine reduced spontaneous pain in humans with neuropathic pain [55]. By contrast, A1R but not A2R activation at the spinal level attenuated spontaneous pain [56]. Our data indicated that A1R receptor was unaltered when EA was delivered at Hua Tuo Jia Ji acupoints. Thus, we suggest that A1R is crucial for local analgesia.

TRPV1 was increased in a complete Freund’s adjuvant-induced inflammatory pain model from day 1 to day 21. Subcutaneous or intrathecal injection of TRPV1 antagonist capsazepine attenuated thermal hyperalgesia in an inflammatory pain model [57]. Wu et al. [58] indicated that injection of capsaicin, a TRPV1 agonist, into the ST36 acupoint relieved inflammatory pain. This suggested that capsaicin replicated the analgesic effect of acupuncture [58]. TRPV4 participated in inflammatory thermal and mechanical hyperalgesia [59]. Chemotherapy-induced neuropathic pain was ameliorated by TRPV4 antisense oligodeoxynucleotide [60]. TRPV4 plays an important role in several pain syndromes such as acute inflammatory, chronic, neuropathic, and chemotherapy-mediated pain. Chen et al. [61] indicated that EA at bilateral ST36 acupoints reduced the potentiation of TRPV1 and TRPV4 in mice with inflammatory pain. Another study [38] demonstrated that activation of mGluRs attenuated glutamatergic input, which explains the analgesic effect of its agonists on neuropathic pain. Chiechio et al. [62] suggested that activation of mGlu2/3 could reduce neuropathic pain [62]. Our data showed that TRPV1, TRPV4, and mGluR3 were not altered by EA performed at Hua Tuo Jia Ji acupoints.

In summary, we conclude that EA at bilateral L4 and L6 of Hua Tuo Jia Ji acupoints significantly reduces rat neuropathic pain, as determined by measuring mechanical and thermal hyperalgesia through von Frey and cold plate tests. We also determined that spinal GABAA receptor—but not A1R, TRPV1, TRPV4, or mGluR3—responded to EA analgesia.

Conflicts of Interest

The authors declare that there are no conflicts of interest associated with this manuscript and there was no significant financial support that could have influenced the outcome.

Authors’ Contributions

S.-W. Jiang performed the animal experiments; Y.-W. Lin participated in discussions and provided help; C.-L. Hsieh participated in protocol design and wrote the manuscript text. S.-W. Jiang and Y.-W. Lin contributed equally to this work. All authors have reviewed and approved the manuscript.


This study was supported by Grant CMU104-S-42 and by Grant DMR-107-167 from China Medical University Hospital. This work was also financially supported by the Chinese Medicine Research Center, China Medical University, from the Featured Areas Research Center Program within the framework of the Higher Education Sprout Project by the Ministry of Education (MOE) in Taiwan.


  1. T. S. Jensen, R. Baron, M. Haanpää et al., “A new definition of neuropathic pain,” PAIN, vol. 152, no. 10, pp. 2204-2205, 2011. View at: Publisher Site | Google Scholar
  2. J. Cheng, J. Long, X. Hui, D. Lei, and H. Zhang, “Effects of microvascular decompression on depression and anxiety in trigeminal neuralgia: A prospective cohort study focused on risk factors and prognosis,” Clinical Neurology and Neurosurgery, vol. 161, pp. 59–64, 2017. View at: Publisher Site | Google Scholar
  3. C. Zhu, Q. Xu, C. Wang, Z. Mao, and N. Lin, “Evidence that CA3 is underling the comorbidity between pain and depression and the co-curation by wu-tou decoction in neuropathic pain,” Scientific Reports, vol. 7, no. 1, p. 11935, 2017. View at: Google Scholar
  4. A. H. Dickenson, V. Chapman, and G. M. Green, “The pharmacology of excitatory and inhibitory amino acid-mediated events in the transmission and modulation of pain in the spinal cord,” General Pharmacology: The Vascular System, vol. 28, no. 5, pp. 633–638, 1997. View at: Publisher Site | Google Scholar
  5. K. Kroenke, E. E. Krebs, and M. J. Bair, “Pharmacotherapy of chronic pain: a synthesis of recommendations from systematic reviews,” General Hospital Psychiatry, vol. 31, no. 3, pp. 206–219, 2009. View at: Publisher Site | Google Scholar
  6. S. Gessi, S. Merighi, D. Fazzi, A. Stefanelli, K. Varani, and P. A. Borea, “Adenosine receptor targeting in health and disease,” Expert Opinion on Investigational Drugs, vol. 20, no. 12, pp. 1591–1609, 2011. View at: Publisher Site | Google Scholar
  7. J. Sawynok, “Adenosine receptor targets for pain,” Neuroscience, 2015. View at: Publisher Site | Google Scholar
  8. F. O. Lima, G. R. Souza, W. A. Verri Jr. et al., “Direct blockade of inflammatory hypernociception by peripheral A1 adenosine receptors: Involvement of the NO/cGMP/PKG/KATP signaling pathway,” PAIN, vol. 151, no. 2, pp. 506–515, 2010. View at: Publisher Site | Google Scholar
  9. M. A. Ackley, R. J. M. Governo, C. E. Cass, J. D. Young, S. A. Baldwin, and A. E. King, “Control of glutamatergic neurotransmission in the rat spinal dorsal horn by the nucleoside transporter ENT1,” The Journal of Physiology, vol. 548, no. 2, pp. 507–517, 2003. View at: Publisher Site | Google Scholar
  10. D. Boison, J.-F. Chen, and B. B. Fredholm, “Adenosine signaling and function in glial cells,” Cell Death & Differentiation, vol. 17, no. 7, pp. 1071–1082, 2010. View at: Publisher Site | Google Scholar
  11. G. Magni and S. Ceruti, “The purinergic system and glial cells: Emerging costars in nociception,” BioMed Research International, vol. 2014, Article ID 495789, 2014. View at: Publisher Site | Google Scholar
  12. A. H. Dickenson, L. C. Stanfa, V. Kontinen, R. Suzuki, and K. Carpenter, “Comment on Svendsen et al., some problems with wind-up and its calculation, PAIN 83 (1999) 109-111,” PAIN, vol. 85, no. 3, p. 524, 2000. View at: Publisher Site | Google Scholar
  13. J. Sawynok, “Adenosine receptor activation and nociception,” European Journal of Pharmacology, vol. 347, no. 1, pp. 1–11, 1998. View at: Publisher Site | Google Scholar
  14. J.-F. Chen, C.-F. Lee, and Y. Chern, “Adenosine receptor neurobiology: overview,” International Review of Neurobiology, vol. 119, pp. 1–49, 2014. View at: Publisher Site | Google Scholar
  15. G. Magni, D. Riccio, and S. Ceruti, “Tackling chronic pain and inflammation through the purinergic system,” Current Medicinal Chemistry, 2017. View at: Google Scholar
  16. S. T. Ang, A. T. H. Lee, F. C. Foo, L. Ng, C.-M. Low, and S. Khanna, “GABAergic neurons of the medial septum play a nodal role in facilitation of nociception-induced affect,” Scientific Reports, vol. 5, Article ID 15419, 2015. View at: Publisher Site | Google Scholar
  17. C. Zhang, R. Chen, Y. Zhang et al., “Reduced GABAergic transmission in the ventrobasal thalamus contributes to thermal hyperalgesia in chronic inflammatory pain,” Scientific Reports, vol. 7, p. 41439, 2017. View at: Publisher Site | Google Scholar
  18. J. Scholz, D. C. Broom, D.-H. Youn et al., “Blocking caspase activity prevents transsynaptic neuronal apoptosis and the loss of inhibition in lamina II of the dorsal horn after peripheral nerve injury,” The Journal of Neuroscience, vol. 25, no. 32, pp. 7317–7323, 2005. View at: Publisher Site | Google Scholar
  19. J. M. Castro-Lopes, M. Malcangio, B. H. Pan, and N. G. Bowery, “Complex changes of GABAA and GABAB receptor binding in the spinal cord dorsal horn following peripheral inflammation or neurectomy,” Brain Research, vol. 679, no. 2, pp. 289–297, 1995. View at: Publisher Site | Google Scholar
  20. J. Castro-Lopes, I. Tavares, and A. Coimbra, “GABA decreases in the spinal cord dorsal horn after peripheral neurectomy,” Brain Research, vol. 620, no. 2, pp. 287–291, 1993. View at: Publisher Site | Google Scholar
  21. R. J. Laing and A. Dhaka, “ThermoTRPs and Pain,” The Neuroscientist, vol. 22, no. 2, pp. 171–187, 2016. View at: Publisher Site | Google Scholar
  22. M. J. Caterina, A. Leffler, A. B. Malmberg et al., “Impaired nociception and pain sensation in mice lacking the capsaicin receptor,” Science, vol. 288, no. 5464, pp. 306–313, 2000. View at: Publisher Site | Google Scholar
  23. J. B. Davis, J. Gray, M. J. Gunthorpe et al., “Vanilloid receptor-1 is essential for inflammatory thermal hyperalgesia,” Nature, vol. 405, no. 6783, pp. 183–187, 2000. View at: Publisher Site | Google Scholar
  24. M. J. Caterina, M. A. Schumacher, M. Tominaga, T. A. Rosen, J. D. Levine, and D. Julius, “The capsaicin receptor: a heat-activated ion channel in the pain pathway,” Nature, vol. 389, no. 6653, pp. 816–824, 1997. View at: Publisher Site | Google Scholar
  25. H. Urano, T. Ara, Y. Fujinami, and B. Yukihiro Hiraoka, “Aberrant TRPV1 expression in heat hyperalgesia associated with trigeminal neuropathic pain,” International Journal of Medical Sciences, vol. 9, no. 8, pp. 690–697, 2012. View at: Publisher Site | Google Scholar
  26. T. Watabiki, T. Kiso, T. Kuramochi et al., “Amelioration of neuropathic pain by novel transient receptor potential vanilloid 1 antagonist AS1928370 in rats without hyperthermic effect,” The Journal of Pharmacology and Experimental Therapeutics, vol. 336, no. 3, pp. 743–750, 2011. View at: Publisher Site | Google Scholar
  27. K. Kobayashi, T. Fukuoka, K. Obata et al., “Distinct expression of TRPM8, TRPA1, and TRPV1 mRNAs in rat primary afferent neurons with Aδ/C-fibers and colocalization with trk receptors,” Journal of Comparative Neurology, vol. 493, no. 4, pp. 596–606, 2005. View at: Publisher Site | Google Scholar
  28. L. Pecze, W. Blum, and B. Schwaller, “Mechanism of capsaicin receptor TRPV1-mediated toxicity in pain-sensing neurons focusing on the effects of Na+/Ca2+ fluxes and the Ca2+-binding protein calretinin,” Biochimica et Biophysica Acta (BBA) - Molecular Cell Research, vol. 1833, no. 7, pp. 1680–1691, 2013. View at: Publisher Site | Google Scholar
  29. M. Tsumura, U. Sobhan, T. Muramatsu et al., “TRPV1-mediated calcium signal couples with cannabinoid receptors and sodium-calcium exchangers in rat odontoblasts,” Cell Calcium, vol. 52, no. 2, pp. 124–136, 2012. View at: Publisher Site | Google Scholar
  30. T. Christoph, G. Bahrenberg, J. De Vry et al., “Investigation of TRPV1 loss-of-function phenotypes in transgenic shRNA expressing and knockout mice,” Molecular and Cellular Neuroscience, vol. 37, no. 3, pp. 579–589, 2008. View at: Publisher Site | Google Scholar
  31. H.-Y. Liao, C.-L. Hsieh, C.-P. Huang, and Y.-W. Lin, “Electroacupuncture attenuates CFA-induced inflammatory pain by suppressing Nav1.8 through S100B, TRPV1, opioid, and adenosine pathways in mice,” Scientific Reports, vol. 7, Article ID 42531, p. 42531, 2017. View at: Publisher Site | Google Scholar
  32. S. M. Brierley, A. J. Page, P. A. Hughes et al., “Selective role for TRPV4 ion channels in visceral sensory pathways,” Gastroenterology, vol. 134, no. 7, pp. 2059–2069, 2008. View at: Publisher Site | Google Scholar
  33. A. D. Grant, G. S. Cottrell, S. Amadesi et al., “Protease-activated receptor 2 sensitizes the transient receptor potential vanilloid 4 ion channel to cause mechanical hyperalgesia in mice,” The Journal of Physiology, vol. 578, no. 3, pp. 715–733, 2007. View at: Publisher Site | Google Scholar
  34. J. P. M. White, M. Cibelli, L. Urban, B. Nilius, J. G. McGeown, and I. Nagy, “TRPV4: Molecular conductor of a diverse orchestra,” Physiological Reviews, vol. 96, no. 3, pp. 911–973, 2016. View at: Publisher Site | Google Scholar
  35. R. Strotmann, C. Harteneck, K. Nunnenmacher, G. Schultz, and T. D. Plant, “OTRPC4, a nonselective cation channel that confers sensivity to extracellular osmolarity,” Nature Cell Biology, vol. 2, no. 10, pp. 695–702, 2000. View at: Publisher Site | Google Scholar
  36. D.-S. Cao, S.-Q. Yu, and L. S. Premkumar, “Modulation of transient receptor potential vanilloid 4-mediated membrane currents and synaptic transmission by protein kinase C,” Molecular Pain, vol. 5, article 5, 2009. View at: Publisher Site | Google Scholar
  37. M. Hollmann and S. Heinemann, “Cloned glutamate receptors,” Annual Review of Neuroscience, vol. 17, pp. 31–108, 1994. View at: Publisher Site | Google Scholar
  38. H.-M. Zhang, S.-R. Chen, and H.-L. Pan, “Effects of activation of group III metabotropic glutamate receptors on spinal synaptic transmission in a rat model of neuropathic pain,” Neuroscience, vol. 158, no. 2, pp. 875–884, 2009. View at: Publisher Site | Google Scholar
  39. C.-T. Kuo, Y.-W. Lin, N.-Y. Tang, C.-Y. Cheng, and C.-L. Hsieh, “Electric stimulation of the ears ameliorated learning and memory impairment in rats with cerebral ischemia-reperfusion injury,” Scientific Reports, vol. 6, Article ID 20381, 2016. View at: Publisher Site | Google Scholar
  40. E.-T. Liao, N.-Y. Tang, Y.-W. Lin, and C. Liang Hsieh, “Long-term electrical stimulation at ear and electro-acupuncture at ST36-ST37 attenuated COX-2 in the CA1 of hippocampus in kainic acid-induced epileptic seizure rats,” Scientific Reports, vol. 7, no. 1, p. 472, 2017. View at: Publisher Site | Google Scholar
  41. M. Choowanthanapakorn, K.-W. Lu, J. Yang, C.-L. Hsieh, and Y.-W. Lin, “Targeting TRPV1 for Body Weight Control using TRPV1-/-Mice and Electroacupuncture,” Scientific Reports, vol. 5, Article ID 17366, 2015. View at: Publisher Site | Google Scholar
  42. K.-W. Lu, C.-K. Hsu, C.-L. Hsieh, J. Yang, and Y.-W. Lin, “Probing the effects and mechanisms of electroacupuncture at ipsilateral or contralateral ST36-ST37 acupoints on CFA-induced inflammatory pain,” Scientific Reports, vol. 6, Article ID 22123, 2016. View at: Publisher Site | Google Scholar
  43. L. T. Yen, C. L. Hsieh, H. C. Hsu, and Y. W. Lin, “Targeting ASIC3 for relieving mice fibromyalgia pain: roles of electroacupuncture, opioid, and adenosine,” Scientific Reports, vol. 7, p. 46663, 2017. View at: Publisher Site | Google Scholar
  44. S. H. Tae, “The effect of 2 Hz and 100 Hz electrical stimulation of acupoint on ankle sprain in rats,” Journal of Korean Medical Science, vol. 22, no. 2, pp. 347–351, 2007. View at: Publisher Site | Google Scholar
  45. R. Zhang, L. Lao, K. Ren, and B. M. Berman, “Mechanisms of acupuncture-electroacupuncture on persistent pain,” Anesthesiology, vol. 120, no. 2, pp. 482–503, 2014. View at: Publisher Site | Google Scholar
  46. B. B. Abuaisha, J. B. Costanzi, and A. J. M. Boulton, “Acupuncture for the treatment of chronic painful peripheral diabetic neuropathy: a long-term study,” Diabetes Research and Clinical Practice, vol. 39, no. 2, pp. 115–121, 1998. View at: Publisher Site | Google Scholar
  47. G. Cruccu, T. Z. Aziz, L. Garcia-Larrea et al., “EFNS guidelines on neurostimulation therapy for neuropathic pain,” European Journal of Neurology, vol. 14, no. 9, pp. 952–970, 2007. View at: Publisher Site | Google Scholar
  48. H. Hsu, N. Tang, Y. Lin, T. Li, H. Liu, and C. Hsieh, “Effect of electroacupuncture on rats with chronic constriction injury-induced neuropathic pain,” The Scientific World Journal, vol. 2014, Article ID 129875, 9 pages, 2014. View at: Publisher Site | Google Scholar
  49. J. R. T. Silva, M. L. Silva, and W. A. Prado, “Analgesia induced by 2- or 100-Hz electroacupuncture in the rat tail-flick test depends on the activation of different descending pain inhibitory mechanisms,” The Journal of Pain, vol. 12, no. 1, pp. 51–60, 2011. View at: Publisher Site | Google Scholar
  50. M. Zienowicz, A. Wisłowska-Stanek, M. Lehner et al., “Fluoxetine attenuates the effects of pentylenetetrazol on rat freezing behavior and c-Fos expression in the dorsomedial periaqueductal gray,” Neuroscience Letters, vol. 414, no. 3, pp. 252–256, 2007. View at: Publisher Site | Google Scholar
  51. J.-H. Park, J.-B. Han, S.-K. Kim et al., “Spinal GABA receptors mediate the suppressive effect of electroacupuncture on cold allodynia in rats,” Brain Research, vol. 1322, pp. 24–29, 2010. View at: Publisher Site | Google Scholar
  52. G. G. Xing, F. Y. Liu, X. X. Qu, J. S. Han, and Y. Wan, “Long-term synaptic plasticity in the spinal dorsal horn and its modulation by electroacupuncture in rats with neuropathic pain,” Experimental Neurology, vol. 208, no. 2, pp. 323–332, 2007. View at: Google Scholar
  53. N. Goldman, M. Chen, T. Fujita et al., “Adenosine A1 receptors mediate local anti-nociceptive effects of acupuncture,” Nature Neuroscience, vol. 13, no. 7, pp. 883–888, 2010. View at: Publisher Site | Google Scholar
  54. T. Takano, X. Chen, F. Luo et al., “Traditional acupuncture triggers a local increase in adenosine in human subjects,” The Journal of Pain, vol. 13, no. 12, pp. 1215–1223, 2012. View at: Publisher Site | Google Scholar
  55. J. C. Eisenach, R. L. Rauck, and R. Curry, “Intrathecal, but not intravenous adenosine reduces allodynia in patients with neuropathic pain,” PAIN, vol. 105, no. 1-2, pp. 65–70, 2003. View at: Publisher Site | Google Scholar
  56. P. K. Zahn, H. Straub, M. Wenk, and E. M. Pogatzki-Zahn, “Adenosine A1 but not A2a receptor agonist reduces hyperalgesia caused by a surgical incision in rats: A pertussis toxin-sensitive G protein-dependent process,” Anesthesiology, vol. 107, no. 5, pp. 797–806, 2007. View at: Publisher Site | Google Scholar
  57. H. Luo, I. S. Xu, Y. Chen et al., “Behavioral and electrophysiological evidence for the differential functions of TRPV1 at early and late stages of chronic inflammatory nociception in rats,” Neurochemical Research, vol. 33, no. 10, pp. 2151–2158, 2008. View at: Publisher Site | Google Scholar
  58. S.-Y. Wu, W.-H. Chen, C.-L. Hsieh, and Y.-W. Lin, “Abundant expression and functional participation of TRPV1 at Zusanli acupoint (ST36) in mice: mechanosensitive TRPV1 as an “acupuncture-responding channel”,” BMC Complementary and Alternative Medicine, vol. 14, p. 96, 2014. View at: Publisher Site | Google Scholar
  59. N. Alessandri-Haber, O. A. Dina, E. K. Joseph, D. Reichling, and J. D. Levine, “A transient receptor potential vanilloid 4-dependent mechanism of hyperalgesia is engaged by concerted action of inflammatory mediators,” The Journal of Neuroscience, vol. 26, no. 14, pp. 3864–3874, 2006. View at: Publisher Site | Google Scholar
  60. N. Alessandri-Haber, O. A. Dina, J. J. Yeh, C. A. Parada, D. B. Reichling, and J. D. Levine, “Transient Receptor Potential Vanilloid 4 Is Essential in Chemotherapy-Induced Neuropathic Pain in the Rat,” The Journal of Neuroscience, vol. 24, no. 18, pp. 4444–4452, 2004. View at: Publisher Site | Google Scholar
  61. W.-H. Chen, J. T. C. Tzen, C. L. Hsieh et al., “Attenuation of TRPV1 and TRPV4 expression and function in mouse inflammatory pain models using electroacupuncture,” Evidence-Based Complementary and Alternative Medicine, vol. 2012, Article ID 636848, 12 pages, 2012. View at: Publisher Site | Google Scholar
  62. S. Chiechio, A. Copani, D. Melchiorri et al., “Metabotropic receptors as targets for drugs of potential use in the treatment of neuropathic pain,” Journal of Endocrinological Investigation, vol. 27, no. 6, pp. 171–176, 2004. View at: Publisher Site | Google Scholar

Copyright © 2018 Siao-Wei Jiang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

More related articles

1209 Views | 289 Downloads | 5 Citations
 PDF  Download Citation  Citation
 Download other formatsMore
 Order printed copiesOrder

Related articles

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.